At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Pre-Mkt 04-15 07:52:03 EDT
147.01
+10.71
+7.86%
盘前145.24
-1.77-1.20%
07:51 EDT
High148.00Low134.66Vol8.20M
Open136.50D1 Closing136.30Amplitude9.79%
Mkt Cap29.13BTradable Cap26.31BTotal Shares198.17M
T/O1.17BT/O Rate4.58%Tradable Shares179.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-Revolution Medicines falls premarket after doubling capital raise to $2 bln
Reuters  ·  11 minutes ago
BUZZ-Revolution Medicines falls premarket after doubling capital raise to $2 bln
Revolution Medicines: Offering 10.6 Mln Shares of Common Stock, $500 Mln Aggregate Convertible Senior Notes - SEC Filing
THOMSON REUTERS  ·  18:13
Revolution Medicines: Offering 10.6 Mln Shares of Common Stock, $500 Mln Aggregate Convertible Senior Notes - SEC Filing
Revolution Medicines 10.563M share Secondary priced at $142.00
TIPRANKS  ·  17:50
Revolution Medicines 10.563M share Secondary priced at $142.00
Revolution Medicines prices USD 500 million 0.5% convertible senior notes due 2033
Reuters  ·  12:41
Revolution Medicines prices USD 500 million 0.5% convertible senior notes due 2033
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
GlobeNewswire  ·  12:41
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says
MT Newswires Live  ·  04-14 23:42
Revolution Medicines Facing Further Upside After Daraxonrasib's Results, RBC Says
BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug
Reuters  ·  04-14 21:38
BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug
Revolution Medicines Reports Positive Phase 3 Trial Results for Pancreatic Cancer Drug
Deep News  ·  04-14 21:13
Revolution Medicines Reports Positive Phase 3 Trial Results for Pancreatic Cancer Drug
Revolution Medicines price target raised to $200 from $140 at Evercore ISI
TIPRANKS  ·  04-14 19:56
Revolution Medicines price target raised to $200 from $140 at Evercore ISI
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  04-14 19:47
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk
Revolution Medicines Inc : H.c. Wainwright Raises Target Price to $169 From $73
THOMSON REUTERS  ·  04-14 18:11
Revolution Medicines Inc : H.c. Wainwright Raises Target Price to $169 From $73
Revolution Medicines Inc : RBC Raises Target Price to $162 From $140
THOMSON REUTERS  ·  04-14 12:11
Revolution Medicines Inc : RBC Raises Target Price to $162 From $140
Revolution Medicines files to sell $750M of common stock
TIPRANKS  ·  04-14 05:10
Revolution Medicines files to sell $750M of common stock
BRIEF-Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes
Reuters  ·  04-14 04:54
BRIEF-Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes
Revolution Medicines Shares Down 1.6% After the Bell; Announces Proposed Offerings of Common Stock and Convertible Senior Notes
THOMSON REUTERS  ·  04-14 04:20
Revolution Medicines Shares Down 1.6% After the Bell; Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines plans USD 750 million follow-on common stock offering
Reuters  ·  04-14 04:03
Revolution Medicines plans USD 750 million follow-on common stock offering
Revolution Medicines Inc - to Offer $750 Mln Common Stock and $250 Mln Convertible Senior Notes Due 2033
THOMSON REUTERS  ·  04-14 04:01
Revolution Medicines Inc - to Offer $750 Mln Common Stock and $250 Mln Convertible Senior Notes Due 2033
BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
Reuters  ·  04-14 01:50
BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Dow Jones  ·  04-14 00:56
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies
TIPRANKS  ·  04-14 00:11
Bar remains unchanged for Erasca after Revolution’s ‘clear win,’ says Jefferies

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--